F
unctional tricuspid regurgitation (TR) is common, whether in association with mitral or aortic valve disease or presenting as an isolated valvular disease. Several studies have shown that TR is associated with poor patient outcomes, although a cause-and-effect relationship of TR to mortality has not been proven. Similarly, the impact of surgical treatment of TR on outcomes needs well-controlled randomized trials that are under planning. 1 The current professional society guidelines for TR treatment are based on expert opinions with a level of evidence C for all indications. 2 Transcatheter therapies for valvular heart disease are often based on established surgical techniques. When surgical therapy has well-studied benefits, including a reduction in mortality (eg, aortic valve replacement for aortic stenosis), percutaneous therapies can be compared to surgery with survival as an end point. Similarly, the safety of surgical therapies (eg, surgical aortic valve replacement) can serve as a benchmark for the safety of percutaneous treatment. However, in establishing percutaneous treatments for TR, several challenges are found: (1) the severity of TR and right ventricle dysfunction are often difficult to determine, (2) the impact of TR on mortality or heart failure outcomes is not as clearly defined, and (3) surgical treatments are multiple without robust data for indications and outcomes. It is important to note that the US Food and Drug Administration is interested in providing expedited access for devices that fill an unmet clinical need by demonstrating appropriate intermediate and surrogate end points. 3 Therefore, the aforementioned challenges also present opportunities to better define how trials for percutaneous treatments of TR can be conducted as we move forward (Table) .
In this issue of Circulation, Nickenig and colleagues 5 describe their multicenter experience in using the MitraClip for the treatment of functional TR. This report is the largest to apply the MitraClip in TR, for which the authors should be congratulated. Among 64 patients (including 22 with concomitant MitraClip placement for mitral regurgitation) treated at 10 centers, they demonstrated an improvement in TR parameters and New York Heart Association class. It is important to note that no intraprocedural deaths occurred or no need for emergent cardiac surgery was indicated.
Several learning points surround the novel use of the MitraClip for TR from this experience. First, the transfemoral approach appears to be the favored approach with clip placement at the anteroseptal commissure (if possible). Second, imaging is of critical importance for success, and transthoracic echo is an important adjunct to the transeophageal echocardiogram. Finally, treatment response is dependent on proper patient selection and with the current state of knowledge is difficult to fully understand.
The current study has a number of limitations, in many ways similar to other literature published on TR. The authors do not provide the specific anatomic details re-
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garding inclusion (or exclusion) based on tricuspid leaflet morphology, annular dimensions, and leaflet restriction. As such, it is unclear whether certain anatomy may be more or less likely to produce a better result. Additionally, as with previous heart failure trials, the current investigators report on clinical outcomes using relatively subjective outcome measures, such as New York Heart Association class. As discussed below, the true efficacy of this treatment is therefore difficult to appreciate. This is a highly comorbid patient population, and the authors are commended on the low in-hospital mortality of 5%. However, without longer-term clinical or echocardiographic follow-up, observations regarding durability of repair and its impact on clinical outcomes cannot be made.
These limitations also highlight the challenges and opportunities for future evaluations of percutaneous tricuspid valve (TV) therapies.
DEFINING TV ANATOMY AND PATHOLOGY
The TV is large with an area of 7 to 10 cm 2 . The annulus is composed of fibrous tissue with ill-defined borders and tends to become circular and flattened with right ventricle or right atrium enlargement. Because most patients with TR have annular dilatation as their primary mechanism, standardizing measurements can be helpful. The annulus is a dynamic structure, therefore a 3-dimensional dataset acquired at specific times of the cardiac cycle for patients in sinus rhythm or atrial fibrillation should be delineated. This approach will be most relevant to annuloplasty techniques such as the Millipede (Millipede LLC), Tricinch (4Tech Cardio), Cardioband (Valtech Cardio), and Trialign (Mitralign Inc) systems as well as spacer devices such as the Forma (Edwards Lifesciences).
With regard to the TV leaflets, the anterior is largest and the septal is smallest. As pointed out in this study, the MitraClip commonly approximates the anterior and septal leaflets, although this fact may be driven more by feasibility than pathoanatomy. With regard to anatomic characterization for use of leaflet-repair techniques such as the MitraClip, a granular understanding of leaflet anatomy (ie, leaflet length, coaptation depth, coaptation length, tenting area, etc) will be important. The authors have admirably tried to characterize leaflet anatomy and function in this report, but a more thorough analysis to predict outcomes based on preprocedural anatomy may allow better patient selection and consistently favorable results.
Additionally, the imaging modality used to acquire these data (computerized tomography, transthoracic echocardiography, or transesophageal echocardiography) should also be clearly defined and standard protocols for measurement outlined. 2, 4 Load-dependent factors should be considered and may include factors such as invasive right atrium pressure or noninvasive inferior vena cava size and dynamics.
DEFINING TR SEVERITY
It is important to recognize that severity of TR is difficult to measure accurately. 6 Although the current report demonstrated an echocardiographic reduction in TR, corelab adjudication was not available. Reporting of different parameters should be standardized for transthoracic echocardiography, transesophageal echocardiography, cardiac magnetic resonance, and invasive hemodynamics (Table) . 2 Furthermore, because TR can be exercise-and load-dependent, understanding and standardizing these parameters as part of the evaluation is imperative.
OUTCOME MEASURES IN TR TRIALS
As with trials assessing the treatment of functional mitral regurgitation percutaneously, it will be important to define clinically appropriate end points for treating TR in addition to echocardiographic parameters. It has become increasingly clear that the New York Heart Association class reported in this article is highly subjective. For instance, in the current report, a striking improvement is found in the New York Heart Association class but a relatively small increase in 6-minute walk distance of 16 meters. Consistently utilizing objective measures such as 6-minute walk distance, the Minnesota Living With Heart Failure questionnaire, and heart failure hospitalization frequency will be helpful. 7 Other clinical end points specific to TR trials, including additional measures of right heart failure such as peripheral edema (or body weight), ascites, and liver function tests, can be included. Additionally, natriuretic peptides, as reported in this study, may be a reasonable secondary end point given the substantial background of data that exist in the population with heart failure. 7 The comparator arm for new devices should also be considered. Although many catheter valve therapies are held to the standard of surgical repair/replacement (eg, aortic stenosis), this approach may not appropriate for tricuspid disease because of the heterogeneous nature of surgical selection/treatment, comorbid conditions, and complexities in outcome evaluation. The most reasonable comparison is optimal medical therapy, including diuretics. Again, because of the high presence of comorbidities, including chronic kidney disease, the definition of optimal medical therapy may require further customization for this population.
PATIENT SELECTION
Appropriate patient selection is key for any clinical investigation. Despite the low procedural mortality in this series, the long-term impact of TR reduction using MitraClip implantation is not provided for this group of patients with comorbid illnesses. The authors have taken great effort to document right ventricular function, pulmonary hypertension, and other cardiac and noncardiac comorbidities. This effort is especially important because the enrollment of patients with late-stage disease may make new therapies look inappropriately futile.
One of the indications for surgical TV repair at the time of mitral valve surgery is based on annular size (diameter >40 mm) rather than severity of TR, with the presumption that TR will ensue if annular dilatation is not treated. This notion is likely a bridge too far in the early era of percutaneous TV repair when we are just trying to establish the technical feasibility of these procedures, but it may be important in the future.
In summary, Nickenig and colleagues 5 report the intial experience of MitraClip placement as an innovative therapy for TR. Because this treatment is not currently treatment in the United States, patients with severe TR who have failed medical heart failure therapies should be considered for 1 of the various clinical trials currently underway of devices designed for percutaneous TR treatment. In the absence of clinical trial enrollment feasibility, the current report suggests that patients may demonstrate clinical benefit from off-label use of the MitraClip device for the treatment of TR when performed by experienced operators.
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